Immatics has appointed Amie Krause as chief people officer, effective Oct. 27, in a newly established role focused on organizational development as the clinical-stage biopharmaceutical company prepares for commercial operations.
Krause will lead human resources for the Houston and Tuebingen, Germany-based company, which is developing cancer therapies. She brings more than 20 years of experience in HR leadership across global biopharmaceutical companies.
“As we enter our next phase of transforming into a commercial-stage enterprise, we are delighted to welcome Amie,” said Harpreet Singh, chief executive officer and co-founder of Immatics. “Her experience in building high-performing teams as well as enhancing organizational excellence and efficiency will help position us for continued success as we strengthen our global leadership in precision targeting of PRAME.”
Background in cell therapy and biotech
Krause joins Immatics from Dompé, where she served as chief human resources officer. Before that, she was chief people officer at Revance Therapeutics and Atara Biotherapeutics, a cell therapy company.
She spent more than 10 years at Amgen, where she held senior HR roles including leading initiatives for global commercial operations across the Americas, Europe, Asia, Africa and the Middle East.
Company transition to commercial stage
According to Singh, Krause will support the company as it advances its pipeline of product candidates and prepares for commercialization of its lead cell therapy candidate, anzu-cel.
“Immatics is at a crucial stage in its journey to deliver innovative therapies to patients with cancer. I am honored to be joining at such a transformative time and working alongside a talented team,” said Amie Krause, chief people officer of Immatics. “Building on Immatics’ strategic vision and diverse talent, I look forward to fostering a culture that drives organizational excellence and ensures we are ready to deliver on the promise of our PRAME franchise.”
Academic involvement
In addition to her industry work, Krause serves as an adjunct professor at California Lutheran University’s School of Management and guest lecturer at the University of Southern California and the University of Alabama.
She holds a bachelor of science in business management and an MBA from California Lutheran University.
Immatics develops TCR T-cell therapies and TCR bispecifics targeting PRAME, a protein expressed in more than 50 cancers, according to the company.
